Analytical Data
-
基因名
CRACC/SLAMF7
- Application
-
别名
CD319; CRACC; 19A; CS1; CD2-like receptor-activating cytotoxic cells; Membrane protein FOAP-12
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NQ25
-
表达区间
Ser23~Met226
-
分子量
28kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CRACC, also known as SLAMF7 (Signaling Lymphocytic Activation Molecule Family Member 7), is a member of the SLAM family of receptors that play crucial roles in immune system regulation. This protein is primarily expressed on the surface of natural killer (NK) cells and certain leukocyte populations, where it participates in mediating immune responses, particularly in the context of tumor immunity and autoimmune diseases. The study of CRACC/SLAMF7 has gained traction due to its potential as a therapeutic target in cancer immunotherapy. Researchers have observed that SLAMF7 can enhance NK cell activation and cytotoxicity against malignant cells, suggesting that it may boost anti-tumor immunity. Additionally, the understanding of CRACC’s role in modulating immune cell interactions and signaling pathways has opened avenues for developing recombinant proteins that can be harnessed to improve immune responses. Given its unique expression pattern and function, CRACC/SLAMF7 recombinant proteins are being investigated for their ability to engage and activate immune cells, potentially leading to novel treatment strategies for various malignancies. This research is particularly relevant in the era of personalized medicine, where targeted immune therapies are reshaping cancer treatment paradigms. Thus, the recombinant study of CRACC/SLAMF7 is pivotal for uncovering novel therapeutic interventions and enhancing the efficacy of existing immunotherapeutic strategies.
